- Home
- UFPI vs ADMA Comparison
UFPI vs ADMA Comparison
Compare UFPI & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFPI
- ADMA
- Stock Information
- Founded
- UFPI 1955
- ADMA 2004
- Country
- UFPI United States
- ADMA United States
- Employees
- UFPI N/A
- ADMA N/A
- Industry
- UFPI Forest Products
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UFPI Basic Materials
- ADMA Health Care
- Exchange
- UFPI Nasdaq
- ADMA Nasdaq
- Market Cap
- UFPI 5.8B
- ADMA 5.1B
- IPO Year
- UFPI 1993
- ADMA N/A
- Fundamental
- Price
- UFPI $104.79
- ADMA $18.68
- Analyst Decision
- UFPI Strong Buy
- ADMA Strong Buy
- Analyst Count
- UFPI 4
- ADMA 3
- Target Price
- UFPI $143.00
- ADMA $27.67
- AVG Volume (30 Days)
- UFPI 543.2K
- ADMA 3.3M
- Earning Date
- UFPI 07-29-2025
- ADMA 08-07-2025
- Dividend Yield
- UFPI 1.34%
- ADMA N/A
- EPS Growth
- UFPI N/A
- ADMA N/A
- EPS
- UFPI 6.11
- ADMA 0.84
- Revenue
- UFPI $6,608,862,000.00
- ADMA $459,381,000.00
- Revenue This Year
- UFPI $0.88
- ADMA $23.35
- Revenue Next Year
- UFPI $4.65
- ADMA $27.67
- P/E Ratio
- UFPI $17.13
- ADMA $22.36
- Revenue Growth
- UFPI N/A
- ADMA 62.23
- 52 Week Low
- UFPI $93.00
- ADMA $10.21
- 52 Week High
- UFPI $141.33
- ADMA $25.67
- Technical
- Relative Strength Index (RSI)
- UFPI 55.87
- ADMA 48.02
- Support Level
- UFPI $102.17
- ADMA $17.90
- Resistance Level
- UFPI $109.80
- ADMA $18.69
- Average True Range (ATR)
- UFPI 3.39
- ADMA 0.63
- MACD
- UFPI 0.58
- ADMA 0.13
- Stochastic Oscillator
- UFPI 70.18
- ADMA 84.98
About UFPI UFP Industries Inc.
UFP Industries Inc is a supplier of lumber to the manufactured housing industry. Today UFP Industries is a multibillion-dollar holding company with subsidiaries around the globe that serve three markets: retail, packaging and construction. Its business segments consist of UFP Retail Solutions, UFP Packaging, UFP Construction, All other and Corporate.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.